Audit: QRS - Prebiotics for Health & Longevity of the ER frontmatter

Audit conducted on 22/08/2026 01:52 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No sourced ER section used by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER contraindication bullets do not use ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Contraindications section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interaction bullets do not use ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Key Interactions section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Protocol section lists more than three distinct actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER states three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER Practical Considerations provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢

Issues 22/08/2026 01:52

Pass rate 100.00%. No issues found.

Issues 22/08/2026 01:42

1. 2.7 — Unexpanded specialist acronyms: First uses of GOS (stop_items, line 543), FODMAP (stop_items, line 545), SIBO (risks_speculative, line 584), and INR (caution_items, line 557) omit the expansions the ER already provides for those terms.

Fixes 22/08/2026 01:42

1. 2.7 — Unexpanded specialist acronyms: Expanded first-use GOS, FODMAP, SIBO, and INR with the ER parenthetical glosses (galactooligosaccharides; fermentable oligo-, di-, mono-saccharides and polyols; small intestinal bacterial overgrowth; international normalized ratio / clotting-time index).

Issues 22/08/2026 01:28

1. 1.2 / 1.3 — Conflicted phrasing dropped: Benefits Low lists “glycemic control” and Risks Medium lists “irritable bowel symptom flare with fructans” without the ER headings’ cautious “Conflicted” flag, which presents those claims as unqualified effects.

2. 1.3 / 9.4 — Antibiotics item truncated: The oral-antibiotics interaction reads “typically resumed after” instead of the ER’s complete key fact that many protocols resume prebiotics after the course ends.

Fixes 22/08/2026 01:28

1. 1.2 / 1.3 — Conflicted phrasing dropped: Restored the ER’s “conflicted” flag on Benefits Low glycemic control and Risks Medium irritable-bowel fructan flare.

2. 1.3 / 9.4 — Antibiotics item truncated: Replaced “typically resumed after” with the ER’s complete key fact “many protocols resume after the course ends”.

Issues 22/08/2026 01:13

1. 1.3 — Scope qualifiers dropped: Live probiotics omits ER “in some formulas” (line 559) and calcium/vitamin D omits “in adolescent and some adult data” (line 560), generalizing both claims.

2. 2.4 / 2.5 — Imperative clinical advice: Key Interactions (lines 553–562) use command phrasing (“separate by at least 4 hours; monitor”, “typically resume after”) instead of presenting the ER’s descriptive facts.

3. 4.3 / 13.3 — SIBO label expanded: Speculative risk (line 584) paraphrases the ER heading “Increased Small-Intestinal Fermentation in SIBO” as “small intestinal bacterial overgrowth”.

4. 8.4 — Stop-item elaborations: Contraindications add GOS “(galactooligosaccharide)” (line 543) and FODMAP “(fermentable oligo-, di-, mono-saccharides and polyols)” (line 545), which are not in the ER bullets.

Fixes 22/08/2026 01:13

1. 1.3 — Scope qualifiers dropped: Restored ER scope on live probiotics (“in some formulas”) and on calcium/vitamin D (“in adolescent and some adult data”).

2. 2.4 / 2.5 — Imperative clinical advice: Rewrote interaction lines from commands (“separate by”, “typically resume after”) to descriptive ER phrasing (“typically separated by”, “typically resumed after”, “INR monitoring”).

3. 4.3 / 13.3 — SIBO label expanded: Replaced “small intestinal bacterial overgrowth” with the ER heading form “SIBO”.

4. 8.4 — Stop-item elaborations: Removed the added GOS “(galactooligosaccharide)” and FODMAP “(fermentable oligo-, di-, mono-saccharides and polyols)” expansions from the contraindication items.

Issues 22/08/2026 01:03

1. 12.3 — Benefit qualifier retained: The Low-tier benefit line (benefits_low) appends “, conflicted” after “glycemic control”. 12.3 requires just the key fact with no qualifiers; the Low tier already encodes evidence strength.

2. 13.3 — Risk qualifier retained: The Medium-tier risk line (risks_medium) appends “, conflicted” after “irritable bowel symptom flare with fructans”. 13.3 requires just the key fact with no qualifiers; the Medium tier already encodes evidence strength.

Fixes 22/08/2026 01:03

1. 12.3 — Benefit qualifier stripped: Removed “, conflicted” from the Low-tier benefits_low line so glycemic control is stated as the key fact only.

2. 13.3 — Risk qualifier stripped: Removed “, conflicted” from the Medium-tier risks_medium line so irritable bowel symptom flare with fructans is stated as the key fact only.

Issues 22/08/2026 00:50

1. 9.5 — Interaction severity classes: QRS caution_items (lines 552–563) drop ER severity classes. Levothyroxine, antacids/iron, narrow-therapeutic-index drugs, and GLP-1 agonists are “Severity: monitor”; stimulant laxatives, other fermentable fibers, and oral antibiotics are “Severity: caution”; live probiotics are “generally useful”; calcium and vitamin D are “Severity: favorable”. Example drugs and time windows are kept, but these severity classes are omitted entirely.

Fixes 22/08/2026 00:50

1. 9.5 — Interaction severity classes: Added compact ER severity tags (monitor, caution, generally useful, favorable) to Key Interactions items that had dropped them. Warfarin and oral antibiotics already carried monitor/caution and were left as-is.

Issues 22/08/2026 00:39

1. 1.1 / 2.15 / 12.3 / 12.4 — Speculative endotoxemia parenthetical: benefits_speculative adds “(bacterial-toxin leak into blood)” after “reduced metabolic endotoxemia”. That gloss is not the ER’s wording, is colloquial, and is a mechanistic parenthetical that benefit items must strip.

2. 4.2 / 4.3 / 9.4 — Synbiotic pairing label: The live-probiotics caution item uses “Live probiotics (synbiotic pairing with a prebiotic)” instead of the ER bold label “Live probiotics (synbiotic pairing):”, adding an elaboration the interaction items must not carry.

Fixes 22/08/2026 00:39

1. 1.1 / 2.15 / 12.3 / 12.4 — Speculative endotoxemia parenthetical: Removed the mechanistic gloss “(bacterial-toxin leak into blood)” from benefits_speculative, leaving “reduced metabolic endotoxemia” as in the ER heading.

2. 4.2 / 4.3 / 9.4 — Synbiotic pairing label: Restored the ER bold label on the live-probiotics caution item, from “synbiotic pairing with a prebiotic” to “synbiotic pairing”.

Issues 22/08/2026 00:27

1. 2.7 — Unexplained medical jargon: Decision-gate and protocol cells drop the ER’s own plain-language expansions and leave specialist terms unexplained, including IgE-mediated, classic galactosemia, acute abdomen, FODMAP, GOS, ISAPP/EFSA, GLP-1, synbiotic, metabolic endotoxemia, and urticaria.

Fixes 22/08/2026 00:33

1. 2.7 — Unexplained medical jargon: Added compact ER-supported glosses for specialist terms in protocol, contraindications, interactions, speculative benefits, and qualitative assessment (ISAPP/EFSA, IgE-mediated, galactosemia, GOS, acute abdomen, FODMAP, GLP-1, synbiotic, metabolic endotoxemia, urticaria).

Issues 22/08/2026 00:16

1. 9.4 — Interaction items miss key facts: Live probiotics (line 559) is only the ER label, omitting the key fact (potentiating for bifidobacteria, still gas-prone). Calcium and vitamin D (line 560) drops the mineral-absorption interaction and keeps a trailing “no routine dose change” clause of the type this item says to strip.

Fixes 22/08/2026 00:16

1. 9.4 — Interaction items miss key facts: Changed Live probiotics from the ER label only to include “potentiating for bifidobacteria, still gas-prone”, and Calcium and vitamin D from the trailing “no routine dose change” clause to the key fact “potentiating for mineral absorption”.

Issues 22/08/2026 00:02

1. 1.1 / 7.3 — Industry-tied wording: At-a-glance (QRS line 433) says weight and blood-fat changes are “partly industry-tied”; the ER Conclusion (line 371) reports that some pooled analyses include authors employed by inulin manufacturers, not that the changes are industry-tied. time_1_sub (QRS line 489) also adds “measurable,” which the ER time-to-effect sentence (line 323) does not use.
2. 1.3 — Strengthened COI claim: Recasting manufacturer-employed authors as “partly industry-tied” in at-a-glance strengthens a conflict-of-interest disclosure into a claim that the findings themselves are industry-tied.
3. 8.4 — FODMAP elaboration added: The low-FODMAP stop item (QRS line 545) adds “(fermentable carbohydrate),” which is not in the ER contraindication bullet (line 275) and is an elaboration rather than the key fact.

Fixes 22/08/2026 00:02

1. 1.1 / 1.3 / 7.3 — Industry-tied wording: Replaced at-a-glance “partly industry-tied” with “some analyses have inulin-manufacturer authors” so the manufacturer-author conflict matches the ER Conclusion. Removed the unsupported word “measurable” from time_1_sub.
2. 8.4 — FODMAP elaboration added: Removed the added parenthetical “(fermentable carbohydrate)” from the low-FODMAP stop item, restoring the ER contraindication wording.